RTP Mobile Logo
RTP On Demand — Breast Cancer, Part I
Released September 2015

Proceedings from a video interview with Drs Lisa A Carey and Eric P Winer on ER-positive, HER2-negative breast cancer, including data review, case-based discussions and downloadable slides. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for medical and radiation oncologists, breast and general surgeons, hematology-oncology fellows and other healthcare providers involved in the treatment of breast cancer.

    Breast cancer remains the most frequently diagnosed cancer in women, and in 2015 in the United States alone the disease will culminate in an estimated 231,840 new cases and 40,290 deaths. Advances in screening and prevention have resulted in a steady down-stage migration at the time of disease presentation, such that only 5% of women have identifiable distant metastases at primary diagnosis. Consequently, the number of individuals living with breast cancer has increased substantially, as has the population “at risk” for recurrent disease. While the diagnosis and treatment of breast cancer remain, in many ways, more advanced than in other solid cancers, challenging issues in the basic management of this disease continue to require refinement.

    Published results from ongoing trials lead to the continuing emergence of new therapeutic agents and changes in the indications for existing treatments. In order to offer optimal patient care, the practicing medical oncologist must be well informed of these advances. To bridge the gap between research and patient care, this program uses a discussion with Drs Lisa A Carey and Eric P Winer about treatment controversies and the integration of key data sets into the practical management of breast cancer.


    • Apply the results of emerging clinical trial data to the best-practice care of patients with breast cancer.
    • Assimilate new clinical trial evidence into the therapeutic algorithm for advanced ER-positive postmenopausal breast cancer.
    • Appreciate the similarities and differences among existing genomic assays, and use this information to select appropriate platforms to assess risk and individualize therapy for patients with invasive and noninvasive early breast cancer.
    • Develop an understanding of emerging efficacy and side-effect data with novel agents and strategies under evaluation for early breast cancer.
    • Counsel appropriately selected patients with breast cancer about participation in ongoing clinical trials investigating novel therapeutic agents and strategies.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue

    This CME activity consists of a video component.

    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Lisa A Carey, MD
    Richardson and Marilyn Jacobs Preyer Distinguished Professor for Breast Cancer Research
    Chief, Division of Hematology and Oncology
    North Carolina Cancer Hospital
    Associate Director for Clinical Research
    Lineberger Comprehensive Cancer Center
    Chapel Hill, North Carolina

    No real or apparent conflicts of interest to disclose.

    Eric P Winer, MD
    Thompson Chair in Breast Cancer Research
    Chief, Division of Women's Cancers
    Dana-Farber Cancer Institute
    Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Contracted Research: Genentech BioOncology.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Celgene Corporation, Eisai Inc, Foundation Medicine, Genomic Health Inc and Lilly.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: September 2015
    Expiration date: September 2016

Acknowledge and close

Watch video
(WIFI is recommended for best performance):

Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors for ER-Positive Breast Cancer (BC)
Recent clinical data with and FDA approval of palbociclib for ER-positive metastatic BC (mBC)
Toxicity profile of palbociclib
Optimal sequencing of palbociclib and everolimus in patients with ER-positive mBC
Integrating fulvestrant or palbociclib with hormonal therapy for the treatment of ER-positive mBC
Emerging clinical data with the novel CDK 4/6 inhibitor abemaciclib in hormone-receptor positive mBC
A 45-year-old woman who developed bone metastases after adjuvant chemohormonal therapy receives palbociclib/letrozole
A woman with ER-positive mBC is enrolled on a clinical trial of the novel CDK 4/6 inhibitor abemaciclib with exemestane
Ongoing clinical investigation of palbociclib for hormone receptor-positive BC in the adjuvant setting
Adverse events associated with CDK inhibitor therapy
Genomic Predictor Assays in Treatment Decision-Making
Adjuvant treatment benefit for a 62-year-old woman with a 1.7-cm node-positive BC and a low Recurrence Score (RS)
Identification of patients with node-positive early BC with low risk of recurrence using genomic predictor assays
Concordance and differences among genomic predictor assays with regard to BC relapse risk
A 62-year-old woman with an HR-positive, T2N0 high-grade IDC and an RS of 48 is unsure of pursuing adjuvant therapy
A 42-year-old woman with a 5-cm Stage IIIA, ER-positive BC and one positive node is considered for neoadjuvant therapy